Literature DB >> 11114716

Overdosage of pamidronate in a patient with renal cell carcinoma.

H Akbulut1, F Icli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11114716     DOI： 10.1007/BF02782202

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  8 in total

1.  Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation.

Authors:  M M Walther; B Patel; P L Choyke; I A Lubensky; C D Vocke; C Harris; D Venzon; W J Burtis; W M Linehan
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

2.  [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].

Authors:  H Kise; K Kobayashi; K Arima; M Yanagawa; H Tochigi; J Kawamura; T Hioki; Y Sugiura
Journal:  Hinyokika Kiyo       Date:  1996-11

Review 3.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Symptomatic hypocalcemia after intravenous pamidronate.

Authors:  E McIntyre; E Bruera
Journal:  J Palliat Care       Date:  1996       Impact factor: 2.250

5.  High dose pamidronate: clinical and biochemical effects in metastatic bone disease.

Authors:  R E Coleman; O P Purohit; J J Vinholes; J Zekri
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

6.  Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center.

Authors:  R Vassilopoulou-Sellin; B M Newman; S H Taylor; V F Guinee
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma.

Authors:  H J Fahn; Y H Lee; M T Chen; J K Huang; K K Chen; L S Chang
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

8.  Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

Authors:  J J Body; J C Dumon
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.